Manufacturers

Work worth doing: Innovative field solutions

Manufacturers

Essential skills for outsourced field solutions teams

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Reimbursement considerations for home infusions

Copay accumulator adjustment programs significantly increase patient financial burden

Manufacturers

How to forge stronger working relationships with payers

Manufacturers

The essential guide to drug commercialization

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

Improve outcomes and reduce costs for emerging therapies

Manufacturers

HTA Quarterly | Fall 2022

Manufacturers

Innovative agreements: Exploring alternative payment models

Manufacturers

Navigating reimbursement and access challenges for novel cell and gene therapies

Research poster: The current impact of ICER assessments on payer decision making

Manufacturers

Differentiate your product with FormularyDecisions®

The drug reimbursement environment in Canada: An overview

HTA Quarterly | Spring 2022

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Equity considerations in US value assessment: Opportunities ahead

Manufacturers

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Manufacturers

Navigating the payer landscape for digital therapeutics

Copay accumulators and the impact on patients

Manufacturers

Work worth doing: FormularyDecisions

Manufacturers

Ebook: Strategic partnerships for unlocking product potential

Manufacturers

Buy-and-bill vs. self-administered: Field services remove barriers across access points

Manufacturers

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

Manufacturers

Checklist: Four things to look for in a field services partner

Manufacturers

Launching field services in the midst of COVID-19

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Manufacturers

Evaluating the modern field reimbursement and access program: key considerations

Manufacturers

Pharma in the field: Heather's story

Manufacturers

Webinar: the growing utilization of copay accumulator programs

It’s the Healthcare of the Future: Telehealth Trends Beyond 2020

Manufacturers

Pharma in the field: Ashley's story

Manufacturers

Pharma in the field: Tierra's story

Case study: Gaining payer attention through digital innovation

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Impact of COVID-19 Pandemic on Patient Access Programs

Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments

Manufacturers

Video: Removing Barriers for Biosimilars

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Manufacturers

Medicare Part B: Do Providers Choose Treatment Based on Payment?

Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Manufacturers

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Manufacturers

What Do Payers Think About Digital Health Technologies

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Biosimilar Coding—Could There Be Billions in Hidden Savings?